Cargando…
Extended follow-up of a comprehensive behavioral (ComB) treatment sample during the COVID-19 pandemic
This study provides the longest follow-up yet for comprehensive behavioral (ComB) treatment of trichotillomania (TTM) (M = 24.59 months after pre-treatment and 15.92 months after the last follow-up point in a recent clinical trial (Carlson et al., 2021), which had shown ComB to be significantly more...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683380/ https://www.ncbi.nlm.nih.gov/pubmed/34956828 http://dx.doi.org/10.1016/j.jocrd.2021.100706 |
_version_ | 1784617405199155200 |
---|---|
author | Flannery, Meghan K. Coyne, Allison F. Carlson, Emily J. Haaga, David.A.F. |
author_facet | Flannery, Meghan K. Coyne, Allison F. Carlson, Emily J. Haaga, David.A.F. |
author_sort | Flannery, Meghan K. |
collection | PubMed |
description | This study provides the longest follow-up yet for comprehensive behavioral (ComB) treatment of trichotillomania (TTM) (M = 24.59 months after pre-treatment and 15.92 months after the last follow-up point in a recent clinical trial (Carlson et al., 2021), which had shown ComB to be significantly more efficacious than minimal attention at post-treatment). This study also examined changes in TTM severity from before to during the COVID-19 pandemic. Participants (N = 23) completed a survey assessing current TTM symptoms, the impact of the pandemic on their coping with TTM, and their experience with ComB treatment. Self-reported symptom severity at this follow-up evaluation fell between the scores obtained at the clinical trial’s pre-treatment assessment and at its last follow-up before the pandemic and did not significantly differ from either time point. Most participants (73%) reported some change in their TTM management since onset of the pandemic, with changes to their environment/routine (61%) and in anxiety (32%) being the most common. Pandemic-related changes were associated with variable outcomes, improving symptoms and management for some while worsening them for others. Use of strategies from ComB had declined since the most recent follow-up, but more than half (55%) of participants reported that strategies from ComB remained useful. |
format | Online Article Text |
id | pubmed-8683380 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86833802021-12-20 Extended follow-up of a comprehensive behavioral (ComB) treatment sample during the COVID-19 pandemic Flannery, Meghan K. Coyne, Allison F. Carlson, Emily J. Haaga, David.A.F. J Obsessive Compuls Relat Disord Article This study provides the longest follow-up yet for comprehensive behavioral (ComB) treatment of trichotillomania (TTM) (M = 24.59 months after pre-treatment and 15.92 months after the last follow-up point in a recent clinical trial (Carlson et al., 2021), which had shown ComB to be significantly more efficacious than minimal attention at post-treatment). This study also examined changes in TTM severity from before to during the COVID-19 pandemic. Participants (N = 23) completed a survey assessing current TTM symptoms, the impact of the pandemic on their coping with TTM, and their experience with ComB treatment. Self-reported symptom severity at this follow-up evaluation fell between the scores obtained at the clinical trial’s pre-treatment assessment and at its last follow-up before the pandemic and did not significantly differ from either time point. Most participants (73%) reported some change in their TTM management since onset of the pandemic, with changes to their environment/routine (61%) and in anxiety (32%) being the most common. Pandemic-related changes were associated with variable outcomes, improving symptoms and management for some while worsening them for others. Use of strategies from ComB had declined since the most recent follow-up, but more than half (55%) of participants reported that strategies from ComB remained useful. Elsevier Inc. 2022-01 2021-12-18 /pmc/articles/PMC8683380/ /pubmed/34956828 http://dx.doi.org/10.1016/j.jocrd.2021.100706 Text en © 2021 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Flannery, Meghan K. Coyne, Allison F. Carlson, Emily J. Haaga, David.A.F. Extended follow-up of a comprehensive behavioral (ComB) treatment sample during the COVID-19 pandemic |
title | Extended follow-up of a comprehensive behavioral (ComB) treatment sample during the COVID-19 pandemic |
title_full | Extended follow-up of a comprehensive behavioral (ComB) treatment sample during the COVID-19 pandemic |
title_fullStr | Extended follow-up of a comprehensive behavioral (ComB) treatment sample during the COVID-19 pandemic |
title_full_unstemmed | Extended follow-up of a comprehensive behavioral (ComB) treatment sample during the COVID-19 pandemic |
title_short | Extended follow-up of a comprehensive behavioral (ComB) treatment sample during the COVID-19 pandemic |
title_sort | extended follow-up of a comprehensive behavioral (comb) treatment sample during the covid-19 pandemic |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683380/ https://www.ncbi.nlm.nih.gov/pubmed/34956828 http://dx.doi.org/10.1016/j.jocrd.2021.100706 |
work_keys_str_mv | AT flannerymeghank extendedfollowupofacomprehensivebehavioralcombtreatmentsampleduringthecovid19pandemic AT coyneallisonf extendedfollowupofacomprehensivebehavioralcombtreatmentsampleduringthecovid19pandemic AT carlsonemilyj extendedfollowupofacomprehensivebehavioralcombtreatmentsampleduringthecovid19pandemic AT haagadavidaf extendedfollowupofacomprehensivebehavioralcombtreatmentsampleduringthecovid19pandemic |